BioCurex Signs Collaboration Agreement with Goshen Cancer Center
A cancer marker allows one to distinguish cancer cells from non-cancerous cells. RECAF(tm) is a cancer marker exclusively developed and patented by BioCurex, Inc. Cancer markers most widely used in the detection and treatment of cancer include AFP, CEA, PSA and Ca125. An ideal cancer marker is a molecule present in all cancer cells but not in normal or benign tumor cells. RECAF(tm) could become the one cancer marker suitable to detect all cancer types. The potential benefit RECAF(tm) offers to patients is a superior diagnostic tool and a new way to deliver targeted therapy.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.